Navigation Links
Bradmer announces 2008 third quarter operational and financial results
Date:11/10/2008

TSX: BMR

TORONTO, Nov. 10 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a clinical oncology company specializing in the development and commercialization of cancer therapies, today announced its 2008 third quarter operational and financial results.

Operational Highlights

During the three months ended September 30, 2008 and the period subsequent to this date, the Company achieved the following milestones related to its operations and its lead drug, Neuradiab(TM), which is being studied in the Phase III GLASS-ART(TM) Trial:

- Maintained budgetary control and reduced quarterly spending;

- Signed clinical study contracts with nine of the initial 16 sites

under active consideration and activated an initial cohort of five

sites, while advancing a pipeline of additional sites in the US

through the contractual, training and regulatory process;

- Initiated dialog with Health Canada for study expansion into key

Canadian sites with the support of the Canadian Brain Cancer

consortium;

- Enrolled the first group of patients in the GLASS-ART Trial and

successfully dosed patients with Neuradiab at multiple sites;

- Announced new data from the most recent Phase II trial indicating that

the mean time to progression free survival was 77 weeks, which

compares favorably with other published results in newly diagnosed

GBM;

- Evaluated a series of technical steps that may allow a two week

extension of the shelf life of Neuradiab beyond the current six-day

specification; and

- Appointed Dr. Donald Kufe, Professor of Medicine, Harvard Medical

School and Director, Experimental Therapeutics Program, Dana-

Farber/Harvard Cancer Center and Charles James Lilly, CA, a senior

partner with a public accounting firm, to the Board of Directors of

the Company.

"The treat
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Bradmer to present at Rodman & Renshaw Healthcare Conference
2. Bradmer receives FDA approval to proceed with Phase III clinical trial
3. Bradmer announces 2008 first quarter operational and financial results
4. Bradmer announces new additions to management team
5. Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
6. Notice of Bradmer Pharmaceuticals Conference Call
7. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
8. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
9. Bradmer announces additions to Scientific Advisory Board
10. Bradmer Medical Isotope Supply For Phase III Trial Secure
11. Bradmer to present at Rodman & Renshaw Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... Aliso Viejo, California (PRWEB) March 29, 2015 ... have revealed a new transition from Pixel Film Studios, ... 12 sports transitions made exclusively for Final Cut Pro ... “We’ve given our users the tools needed to effortlessly ... Film Studios introduces TranSports, a new and uniquely styled ...
(Date:3/28/2015)... AZ. (PRWEB) March 28, 2015 Could ... to a new study by researchers at ... , Produced with the support of the Coffee and ... journal Molecular Psychiatry this past fall, the study—one of ... meta-analysis of genomic data from more than 120,000 regular ...
(Date:3/28/2015)... California-based leading wig brand UniWigs has prepared a mysterious ... the Easter Holidays from today until April 6th. There ... Day. , As the winter fades and spring approaches, ... with religious origins to countries in Europe and the ... best wig provider, UniWigs, would like to offer a ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Pitching speed, player’s ... history of shoulder and elbow injuries, according to new research ... ( AOSSM ) Specialty Day. , “Our findings indicate that ... 20% increase in likelihood of a history of injury, a ... a 12% increase likelihood of a history of injury, and ...
(Date:3/28/2015)... NC (PRWEB) March 28, 2015 Genomic ... with peritoneal mesothelioma, revealing, for the first time, key ... Click here to read the newly posted story ... at the University of British Columbia, the British Columbia ... genome mapping to reveal underlying molecular alterations and mutations ...
Breaking Medicine News(10 mins):Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2
... loses a chunk of its tail fin, it’ll grow back ... can replace surprisingly complex body parts. A tail fin, for ... very intricate structure. It is the fish version of an ... re-grow missing tails and other appendages has fascinated veterinary and ...
... infrastructure and health facilities has revealed that 14 inmates have ... These deaths are believed to have resulted from treatment errors ... been reported that the jail infrastructure lacks adequate doctors, nurses ... for medical conditions ranging from hernia to heart disease. ...
... Research Institute, have identified a sensor that identifies glucose levels. ... It acts like a switch that increases or decreases the ... it helps to convert glucose into fat for the purpose ... X Receptor. Its dual function makes it a potential site ...
... prominently weaker and are at a risk of getting fractured ... from this disease in the U.K. Women suffer from ... drugs used to treat osteoporosis., This group of drugs plays ... menopausal age. Such women face the risk of fractures due ...
... children have reportedly died from malnutrition in Madhya Pradesh's ... a deep-rooted problem afflicting over 80,000 underprivileged children in ... village died Sunday, two-year-old Chhottu died Dec 20 though ... care of him, the activists said., ,"Both deaths ...
... cracker when she was 14 months old that left her ... peanut is enough to trigger an allergic reaction in people ... 4 1/2, in a landmark experiment that set to discover-'Could ... eventually train children's bodies to overcome severe food allergies?' ...
Cached Medicine News:Health News:Regrowth of Zebrafish's Tail Fin may Offer Clues for Treating Human Injuries 2Health News:Regrowth of Zebrafish's Tail Fin may Offer Clues for Treating Human Injuries 3Health News:Glucose Sensor That Controls Glucose Metabolism Identified 2Health News:Optimum Period is Five Years to Treat Osteoporosis: Study 2Health News:Malnutrition Kills Two Kids In Madhya Pradesh 2Health News:Is Your Child Allergic To Peanuts? 2
(Date:3/27/2015)... BioCorRx, Inc. ( BICX ) ... a healthcare solutions organization, which focuses solely on addiction treatment; ... the U.S. alone. The Company created a unique treatment program ... compounded form for outpatient surgical implantation. The Company has exclusive ... New Zealand ) to the specially formulated Naltrexone implant. ...
(Date:3/27/2015)... , March 27, 2015 Levi & Korsinsky ... Inc. (NASDAQ: OHRP ) concerning possible violations of ... by the Company in connection with its study of ... http://zlk.9nl.com/ohr-pharmaceutical-ohrp or contact Joseph E. Levi, ... or by telephone at (212) 363-7500, toll-free: (877) 363-5972. ...
(Date:3/27/2015)... 27, 2015 /CNW Telbec/ - Russell Williams , ... Companies (Rx&D), welcomes the 2015-2016 Quebec Budget, noting the ... on the biopharmaceutical industry. However, the association is concerned ... "We commend the government,s intent to strive for a ... to promote Quebec,s economic development ...
Breaking Medicine Technology:Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3
... 11, 2008, the Joint Advisory Committees of the ... the Drug Safety & Risk Management Advisory Committee, ... Advisory Committee - completed a review of the ... beta-agonists (LABAs). The committees concluded that the benefits ...
... JERSEY CITY, New Jersey and PHILADELPHIA, December 11, ... microRNA-based molecular diagnostics, announced today the,commercial availability of ... now commercially available through Rosetta Genomics,CLIA-certified lab in ... To order the test, physicians may contact 1-888-522-7971, ...
Cached Medicine Technology:AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R) 2AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R) 3AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R) 4Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 2Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 3Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 4Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 5
Diagnose dry eye, assess the effectiveness of permanent punctal occlusion, collagen - dissolvable in 3-5 days, all are 2 mm long. Sterile...
The Multi-Purpose Stand Magnifier is the most versatile stand magnifier. The stand has multiple configurations allowing for all situations where hands-free magnification is needed....
... The aplanatic lens is made ... lens system consisting of two ... clearly defined, distortion-free image. This ... for patients with macular degeneration ...
... Sheets are commonly used for orbital ... The thinner 0.4 mm sheet was ... greater flexibility and to provide a ... the orbit. It is ideally suited ...
Medicine Products: